Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> MutationCaroline Robert, Paolo A. Ascierto, L. Lundgren-Eriksson et al.|New England Journal of Medicine|2014Cited by 5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab TherapyPaolo A. Ascierto, Victoria Atkinson, Georgina V. Long et al.|JAMA Oncology|2018Cited by 345
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced MelanomaCaroline Robert, Victoria Atkinson, Georgina V. Long et al.|Journal of Clinical Oncology|2020Cited by 226
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanomaGeorgina V. Long, Caroline Robert, Victoria Atkinson et al.|Journal of Translational Medicine|2015Cited by 53
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Charlée Nardin, Stéphane Dalle et al.|Journal of the American Academy of Dermatology|2021Cited by 9